Alicia Fong, OncoDerm Research at Mount Sinai Health System and Hematology/Oncology Scribe at NewYork-Presbyterian, shared on LinkedIn:
“Mantle cell lymphoma (MCL) continues to evolve, bringing important questions surrounding risk stratification, frontline treatment selection, and sequencing strategies.
Dr. Peter Martin and Dr. Kami Maddocks discuss the increasingly complex landscape of MCL management, including:
- Frontline therapy: The evolving role of BTK inhibitors, chemo/immunotherapy, and chemo-free approaches.
- High-risk disease: TP53 alterations, blastoid morphology, and the need for more consistent risk definitions to guide treatment decisions.
- MRD monitoring: Its prognostic potential and emerging role in disease surveillance.
- Treatment duration and sequencing: Questions surrounding fixed-duration versus continuous BTK inhibitor therapy and treatment options following covalent BTK inhibitor progression.
- Emerging therapies: The potential role of bispecific antibodies and CAR-T therapy in the evolving MCL treatment landscape.
As treatment strategies continue to advance, individualizing therapy while balancing efficacy, toxicity, and quantity of life remains central to patient care.
Watch the full Clinical Exchange | Spotlight episode on OncoDaily TV: Mantle Cell Lymphoma Treatment: CAR T and Bispecific Antibodies | Kami Maddocks and Peter Martin.
Mantle Cell Lymphoma
Navigating Treatment in an Evolving Landscape
About the Experts
Dr. Peter Martin (NYU Langone Health) and Dr. Kami Maddocks (OSUCCC–James) bring deep expertise in mantle cell lymphoma (MCL), from research to patient care.
A shared goal: Better outcomes for every patient.
One Disease. Different Risk.
Every patient with MCL has a different clinical course.
- Patient Heterogeneity
- TP53 Alterations
- Blastoid Morphology
Understanding risk helps guide more personalized care.
Treatment Decisions
BTK inhibitors are now a preferred frontline option for many patients, with chemo still playing a role in select cases.
Key Factors:
- Disease risk
- Patient factors
- Treatment goals
High-Risk MCL and MRD
Features like TP53 alterations and blastoid morphology may influence treatment.
MRD is a promising tool – though its role in routine care is still evolving.
Key Takeaways
- Individualize treatment
- Balance efficacy and toxicity
- Explore emerging therapies
- Define high-risk with precision
Watch the Full Episode by Scanning the QR Code Below.
You can also read: Mantle Cell Lymphoma: MANGROVE and the Future of Chemotherapy-Free, Risk-Adapted Treatment.
